攝護腺癌在年老時常見的惡性腫瘤之一，攝護腺特異性抗原(prostate specific antigen, PSA)是目前最重要用來早期檢測攝護腺癌的血清腫瘤標誌，但PSA本身無法偵測辨別攝護腺癌之各種型態，故發展各種攝護腺癌之分子依然為科學界所重視，本實驗利用二維電泳 (two-dimensional electrophoresis)與基質輔助雷射脫附游離飛行時間(matrix-assisted laser desorption ionization-time of flight, MALDI-TOF)質譜法來探討正常人和攝護腺癌病人血液蛋白質的差異，與比較攝護腺癌在治療過程中血液蛋白質的變化，我們發現在癌化過程和治療後分別共有31和17個蛋白質表現量改變，目前我們經由SWISS-PROT資料庫比對和基質輔助雷射脫附游離飛行時間方法，已確認了Fibrinogen gamma chain, Fibrinogen alpha/alpha-E chain, major histocompatibility complex, class I, C和Mayven四個蛋白質在癌化時表現量提高。Fibrinogen, MHC在癌化過程中病人血液變化的結果與最近的報告類似, 而Mayven的表現變異則僅在本研究中發現。

Prostate cancer is one of the most common malignant tumors in solid organs of old men. Prostate-specific antigen (PSA) is a valuable prostate cancer biomarker that is now wildly used for population screening, diagnosis, and monitoring of patients with prostate cancer. Howere it is reported that PSA is not feasible to discriminate the progress of prostate cancer, so many investigators still works on developing new biomarker of prostate carcinoma. Here, we propose the study of differentially expressed prostate proteins in blood of patients.
With the aid of two-dimensional polyacrylamide gel electrophoresis (2-DE) and matrix-assisted laser desorption-induced time of flight (MALDI-TOF) mass spectrometry, comparison of normal men and prostate cancer patients serum proteins and analysis protein variation of different stages of prostate cancer serum. We find 31 and 17 protein spots overexpression in cancer development and after treatment, respectively.
At present, with the aid of SWISS-PORT database and MALDI-TOF mass spectrometry, we had identified fibrinogen gamma chain, fibrinogen alpha/alpha-E chain, major histocompatibility complex (MHC), class I, C and Mayven were overexpressed in prostate cancer development, where Mayven is fist reported by us.

中文摘要 I
英文摘要........................... II
縮寫.............................. III
一、攝護腺癌的介紹..................... 1
二、攝護腺癌的分期..................... 1
三、病原學............................. 2
四、已知癌症發生的可能致癌機轉......... 3
五、致癌基因和原致癌基因............... 4
六、腫瘤抑制基因....................... 4
七、男性賀爾蒙接受體................... 5
八、臨床診斷........................... 5
九、攝護腺專一抗原..................... 6
十、攝護腺專一抗原和kallikrein家族..... 7
十一、攝護腺專一抗原的分子形式......... 8
材料................................... 9
方法
實驗儀器............................... 12
實驗商業套組........................... 12
實驗方法
一、檢體來源與製備................... 12
二、蛋白質二維電泳................... 14
三、基質輔助雷射脫附游離/飛行時間質儀器. 19
四、蛋白質一維電泳................... 20
五、西方點墨法....................... 21
結果
一、血清二維電泳以Coomassie blue R350染色. 23
二、以Cibacron Blue 3GA去除血清中白蛋白.. 23
三、血清二維電泳銀染呈色和Swiss Prot 生物資訊中心血漿二維電泳銀圖........................ 23
四、正常人和攝護腺癌病人血清的二維電泳圖比較 24
五、血清二維電泳蛋白質確認................. 25
六、血清和精液PSA的測定.................... 26
七、常人和攝護腺癌病人精液以二維電泳分析比較.26
八、二維電泳分析攝護腺腫大和攝護腺癌病人之攝護腺組織蛋白質差異............................... 26
結果與討論
一、血清樣本蛋白質之二維電泳分析............ 27
二、以SWISS-PROT生物資訊中心的血漿二維電泳圖之蛋白質比較定位.................................. 27
三、攝護腺特異性抗原在SDS-PAGE上的位置...... 28
四、銀染對MALDI-TOF實驗的影響............... 29
五、病人的差異點探討........................ 30
六、差異點在組織和精液中的表現............. 31
結論
參考文獻................................... 33
圖......................................... 40
表......................................... 65

Bander,N.H. et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 33, 233-239 (1997).
Bangma,C.H. & Verhagen,P.C. Blood and serum substances for markers of prostate cancer. Microsc. Res. Tech. 51, 430-435 (2000).
Bosland,M.C., Prinsen,M.K., Rivenson,A. & Weisburger,J.H. Induction of skin and thyroid tumors in male rats by N-methyl-N- nitrosourea after sequential treatment with cyproterone acetate and testosterone propionate: effects of castration, rat strain and time of carcinogen injection. Carcinogenesis 13, 669-674 (1992).
Bruchovsky,N. & Wilson,J.D. The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem. 243, 2012-2021 (1968).
Carter,B.S. et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Natl. Acad. Sci. U. S. A 87, 8751-8755 (1990).
Caskey,C.T., Pizzuti,A., Fu,Y.H., Fenwick,R.G., Jr. & Nelson,D.L. Triplet repeat mutations in human disease. Science 256, 784-789 (1992).
Catalona,W.J. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279, 1542-1547 (1998).
Choe,L.H. & Lee,K.H. A comparison of three commercially available isoelectric focusing units for proteome analysis: the multiphor, the IPGphor and the protean IEF cell. Electrophoresis 21, 993-1000 (2000).
Christensson,A., Laurell,C.B. & Lilja,H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194, 755-763 (1990).
Dhanasekaran,S.M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826 (2001).
Elghany,N.A., Schumacher,M.C., Slattery,M.L., West,D.W. & Lee,J.S. Occupation, cadmium exposure, and prostate cancer. Epidemiology 1, 107-115 (1990).
Espana,F. et al. Quantitative immunoassay for complexes of prostate-specific antigen with alpha2-macroglobulin. Clin. Chem. 42, 545-550 (1996).
Gao,X., Honn,K.V., Grignon,D., Sakr,W. & Chen,Y.Q. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res. 53, 2723-2727 (1993)
Gerner,C. et al. Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis. Thromb. Haemost. 85, 494-501 (2001).
Gianazza,E. & Arnaud,P. A general method for fractionation of plasma proteins. Dye-ligand affinity chromatography on immobilized Cibacron blue F3-GA. Biochem. J. 201 , 129-136 (1982).
Giovannucci,E. et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. U. S. A 94, 3320-3323 (1997).
Giroldi,L.A. & Schalken,J.A. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev. 12, 29-37 (1993).
Gumerlock,P.H., Poonamallee,U.R., Meyers,F.J. & deVere White,R.W. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res. 51, 1632-1637 (1991).
Hachulla,E., Laine,A. & Hayem,A. Alpha 1-antichymotrypsin microheterogeneity in crossed immunoaffinoelectrophoresis with free concanavalin A: a useful diagnostic tool in inflammatory syndrome. Clin. Chem. 34, 911-915 (1988).
Hara,M., Inoue,T., Koyanagi,Y., Yamazaki,H. & Fukuyama,T. [Immunoelectrophoretic studies of the protein components in human seminal plasma (especially its specific component). (Forensic immunological study of body fluids and secretions. VI)]. Nippon Hoigaku Zasshi 23, 117-122 (1969).
Ittmann,M.M. Chromosome 10 alterations in prostate adenocarcinoma (review). Oncol. Rep. 5, 1329-1335 (1998).
Konig,J.J. et al. Cytogenetic characterization of several androgen responsive and unresponsive sublines of the human prostatic carcinoma cell line LNCaP. Urol. Res. 17, 79-86 (1989).
Konishi,N. et al. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 69, 2293-2299 (1992).
Kunimi,K., Bergerheim,U.S., Larsson,I.L., Ekman,P. & Collins,V.P. Allelotyping of human prostatic adenocarcinoma. Genomics 11, 530-536 (1991).
Lara,P.N., Jr. & Meyers,F.J. Treatment options in androgen-independent prostate cancer. Cancer Invest 17, 137-144 (1999).
Lauber,W.M. et al. Mass spectrometry compatibility of two-dimensional gel protein stains. Electrophoresis 22, 906-918 (2001).
Lilja,H. & Abrahamsson,P.A. Three predominant proteins secreted by the human prostate gland. Prostate 12, 29-38 (1988).
Lilja,H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest 76, 1899-1903 (1985).
Lollo,B.A. et al. Improved two-dimensional gel electrophoresis representation of serum proteins by using ProtoClear. Electrophoresis 20, 854-859 (1999).
Lovgren,J., Rajakoski,K., Karp,M., Lundwall a & Lilja,H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun. 238, 549-555 (1997).
Lundgren,R. et al. Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chromosomes. Cancer 4, 16-24 (1992).
Luo,J. et al. alpha-Methylacyl-CoA Racemase: A New Molecular Marker for Prostate Cancer. Cancer Res. 62, 2220-2226 (2002).
Mack,P.C. et al. Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate 34, 145-151 (1998).
McCombs,R.M. Role of oncornaviruses in carcinoma of the prostate. Cancer Treat. Rep. 61, 131-132 (1977).
Meyers,F.J. et al. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 83, 2534-2539 (1998).
Mills,P.K., Beeson,W.L., Phillips,R.L. & Fraser,G.E. Dietary habits and breast cancer incidence among Seventh-day Adventists. Cancer 64, 582-590 (1989).
Pylkkanen,L., Makela,S. & Santti,R. Animal models for the preneoplastic lesions of the prostate. Eur. Urol. 30, 243-248 (1996).
Qian,Y. et al. Two-dimensional gel electrophoresis detects prostate-specific antigen- alpha1-antichymotrypsin complex in serum but not in prostatic fluid. Clin. Chem. 43, 352-359 (1997).
Reed,J.C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol. 7, 541-546 (1995).
Rooney,C., Beral,V., Maconochie,N., Fraser,P. & Davies,G. Case-control study of prostatic cancer in employees of the United Kingdom Atomic Energy Authority. BMJ 307, 1391-1397 (1993).
Sinha,P., Poland,J., Schnolzer,M. & Rabilloud,T. A new silver staining apparatus and procedure for matrix-assisted laser desorption/ionization-time of flight analysis of proteins after two- dimensional electrophoresis. Proteomics. 1, 835-840 (2001).
Soltysik-Espanola,M. et al. Characterization of Mayven, a novel actin-binding protein predominantly expressed in brain. Mol. Biol. Cell 10, 2361-2375 (1999).
Stamey,T.A. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909-916 (1987).
Steele,R., Lees,R.E., Kraus,A.S. & Rao,C. Sexual factors in the epidemiology of cancer of the prostate. J. Chronic. Dis. 24, 29-37 (1971).
Sumner,L.W., Wolf-Sumner,B., White,S.P. & Asirvatham,V.S. Silver stain removal using H2O2 for enhanced peptide mass mapping by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 16, 160-168 (2002).
Sumner,L.W., Wolf-Sumner,B., White,S.P. & Asirvatham,V.S. Silver stain removal using H2O2 for enhanced peptide mass mapping by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 16, 160-168 (2002).
Takahashi,S. et al. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res. 55, 4114-4119 (1995).
Takayama,T.K., Fujikawa,K. & Davie,E.W. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J. Biol. Chem. 272, 21582-21588 (1997).
Vlietstra,R.J., van Alewijk,D.C., Hermans,K.G., van Steenbrugge,G.J. & Trapman,J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 58, 2720-2723 (1998).
Wang,M.C. et al. Prostate antigen: a new potential marker for prostatic cancer. Prostate 2, 89-96 (1981).
Zhau,H.E. et al. Biomarkers associated with prostate cancer progression. J. Cell Biochem. Suppl 19, 208-216 (1994).
Zhau,H.E., Wan,D.S., Zhou,J., Miller,G.J. & von Eschenbach,A.C. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol. Carcinog. 5, 320-327 (1992).